Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 4/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL880528 | 0.82 | CHRM2 (0.56) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL12333780 | 0.82 | CHRM2 (0.56) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL21441814 | 0.82 | CHRM2 (0.56) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL26805930 | 0.82 | CHRM2 (0.56) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL24723670 | 0.77 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPKDM4E | |
| SCHEMBL24723669 | 0.77 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPKDM4E | |
| SCHEMBL24350080 | 0.76 | CHRM2 (0.54) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL15580385 | 0.76 | CHRM2 (0.54) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL2909390 | 0.75 | CHRM2 (0.53) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL31521544 | 0.75 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9526731-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-27 | — | — | US | disclosed |
| EP-1807077-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-23 | — | — | EP | disclosed |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | US | disclosed |
| US-8933091-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-8697716-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-15 | — | — | US | disclosed |
| US-20140005225-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-02 | — | — | US | disclosed |
| EP-2397138-B1 | Aromatic amide derivatives as C-KIT kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-11 | — | — | EP | disclosed |
| US-8557847-B2 | Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-20100256148-A1 | USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-07 | — | — | US | disclosed |
| US-7795279-B2 | Method of inhibiting FLT3 kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| WO-2009058801-A1 | USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-07 | — | — | WO | disclosed |
| EP-1951234-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-06 | — | — | EP | disclosed |
| US-20080051402-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-28 | — | — | US | disclosed |
| EP-1807077-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007048088-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060189623-A1 | Inhibitors of c-fms kinase | ILLIG CARL R | 2006-08-24 | — | — | US | disclosed |
| US-20060148812-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | disclosed |
| WO-2006047277-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189623-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | CHRM2 511/4885CHRM1 513/4885CHRM3 770/4885 |
| US-20100256148-A1 | USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER | SOST, CALCB, CALCA | CHRM2 2630/4885CHRM1 2402/4885CHRM3 1703/4885 |
| US-20140005225-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | CHRM2 3758/4885CHRM1 3807/4885CHRM3 2660/4885 |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | FLT3, MCL1, CSF1R | CHRM2 4373/4885CHRM1 4415/4885CHRM3 4381/4885 |
| US-20060148812-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | CHRM2 511/4885CHRM1 513/4885CHRM3 770/4885 |
| US-20080051402-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | CHRM2 3758/4885CHRM1 3807/4885CHRM3 2660/4885 |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | FLT3, PLK1, PHKG1 | CHRM2 3314/4885CHRM1 3721/4885CHRM3 2262/4885 |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | CHRM2 3758/4885CHRM1 3807/4885CHRM3 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.